Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Aug 29, 2018 12:12pm

170 Views

Post# 28536196

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Updates coming on Monday, Get in or never

I agree 100%,
If anything seeing a small drop with very small volumn is promising.
We didn't see any 1,000,000 shares dumped at market,
All the big guys are still in this.
All the movement is from the retails investors who are scared off because the liver news.
Since no one important is dumping in masses, that's a good sign there is a general belief the potential is still there.
I'm overall encouraged by what we are seeing in the market even if we are 10% down.

Bullboard Posts

Visionstate set to leverage success in the U.S. market